Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · May 20, 2021

Mavacamten Improves Health Status of Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

The Lancet


Additional Info

The Lancet
Mavacamten for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (EXPLORER-HCM): Health Status Analysis of a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial
Lancet 2021 May 14;[EPub Ahead of Print], JA Spertus, JT Fine, P Elliott, CY Ho, I Olivotto, S Saberi, W Li, C Dolan, M Reaney, AJ Sehnert, D Jacoby

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading